VitaNova Life Sciences (VNOV) Revenue (2017 - 2026)

VitaNova Life Sciences has disclosed Revenue across 7 years of filings, most recently posting $321576.0 for Q3 2026.

• Revenue for Q3 2026 came in at $321576.0, up 209.51% year-over-year; the trailing twelve-month figure through Jul 2026 was $3.2 million (up 22.04% YoY), and the FY2026 annual result was $3.0 million, up 13.65% from the prior year.
• Revenue for Q3 2026 stood at $321576.0, down from $1.8 million in the prior quarter.
• Across five years, Revenue topped out at $2.0 million in Q2 2025 and bottomed at $3000.0 in Q2 2023.
• Average Revenue over 5 years is $393700.8, with a median of $108477.0 recorded in 2024.
• The widest annual swing landed in 2023, when Revenue sank 93.33%; it then surged 18053.13% in 2024.
• Year by year, Revenue stood at $10000.0 in 2022, then slumped by 70.0% to $3000.0 in 2023, then jumped by 9637.27% to $292118.0 in 2024, then soared by 46.21% to $427115.0 in 2025, then slipped by 24.71% to $321576.0 in 2026.
• The last three Revenue figures came in at $321576.0 (Q3 2026), $1.8 million (Q2 2026), and $709625.0 (Q1 2026), per Business Quant data.